Bio-Techne Corp
NASDAQ:TECH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bio-Techne Corp
NASDAQ:TECH
|
US |
|
F
|
First Citizens BancShares Inc (Delaware)
XBER:FC6A
|
US |
|
H
|
Hochtief AG
XBER:HOT
|
DE |
|
NTT Data Corp
TSE:9613
|
JP |
|
A
|
AXA SA
XBER:AXAA
|
FR |
|
D
|
Daiei Kankyo Co Ltd
TSE:9336
|
JP |
|
W
|
WEX Inc
SWB:WL9
|
US |
Bio-Techne Corp
Bio-Techne makes the tools scientists use to study cells and disease. Its products include antibodies, proteins, assays, cell and gene therapy reagents, and instruments used in life-science research and clinical testing. The company also sells diagnostic products that help labs detect and monitor certain medical conditions. Its main customers are drug developers, academic and government research labs, biotech companies, and clinical laboratories. Bio-Techne makes money by selling these consumable products, along with instruments and related services, through direct sales and distributors. Because many of its products are used repeatedly in research and testing workflows, it plays a steady supplier role in the life-science supply chain. What makes Bio-Techne different is that it sits close to the basic science stage of medicine. Instead of making finished drugs, it sells the specialized materials and testing tools that other companies and labs need to discover, develop, and validate those drugs and diagnostics. That gives it exposure to a wide range of research and healthcare end markets.
Bio-Techne makes the tools scientists use to study cells and disease. Its products include antibodies, proteins, assays, cell and gene therapy reagents, and instruments used in life-science research and clinical testing. The company also sells diagnostic products that help labs detect and monitor certain medical conditions.
Its main customers are drug developers, academic and government research labs, biotech companies, and clinical laboratories. Bio-Techne makes money by selling these consumable products, along with instruments and related services, through direct sales and distributors. Because many of its products are used repeatedly in research and testing workflows, it plays a steady supplier role in the life-science supply chain.
What makes Bio-Techne different is that it sits close to the basic science stage of medicine. Instead of making finished drugs, it sells the specialized materials and testing tools that other companies and labs need to discover, develop, and validate those drugs and diagnostics. That gives it exposure to a wide range of research and healthcare end markets.
Revenue: Bio-Techne reported Q3 revenue of $311.4 million, down 2% year over year, with underlying organic growth of 2% after adjusting for timing and other one-time items.
Margins: Adjusted operating margin was 34.2%, up 310 basis points sequentially, showing strong profitability even in a mixed demand environment.
Biotech Weakness: Emerging biotech spending was softer than expected and declined high single digits, which management said was the main reason the quarter came in below its underlying trend.
Strong Spots: Large pharma grew low double digits for its sixth straight quarter, China posted its fourth consecutive quarter of organic growth, and Spatial Biology delivered mid-teens growth.
Outlook: Management expects Q4 organic growth to be approximately flat, with low single-digit underlying growth excluding the temporary cell therapy headwind.
FY27 View: Management said it would be disappointed not to deliver at least mid-single-digit growth in fiscal 2027, citing improving biotech funding, a steadier academic market and easier comparisons.
